KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short-term Investments (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Short-term Investments data on record, last reported at $79.9 million in Q4 2025.

  • For Q4 2025, Short-term Investments fell 61.57% year-over-year to $79.9 million; the TTM value through Dec 2025 reached $79.9 million, down 61.57%, while the annual FY2025 figure was $79.9 million, 61.57% down from the prior year.
  • Short-term Investments reached $79.9 million in Q4 2025 per PCRX's latest filing, down from $98.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $559.8 million in Q3 2021 and bottomed at $70.8 million in Q4 2021.
  • Average Short-term Investments over 5 years is $215.0 million, with a median of $170.8 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: crashed 83.2% in 2021, then surged 160.5% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $70.8 million in 2021, then soared by 160.5% to $184.5 million in 2022, then plummeted by 32.1% to $125.3 million in 2023, then soared by 65.9% to $207.8 million in 2024, then plummeted by 61.57% to $79.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $79.9 million in Q4 2025, $98.7 million in Q3 2025, and $145.4 million in Q2 2025.